Related references
Note: Only part of the references are listed.Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series
Takashi Yamamura et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)
Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder
Trygve Holmoy et al.
JOURNAL OF NEUROLOGY (2021)
Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies
Su-Hyun Kim et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?
Friederike Held et al.
IMMUNOTARGETS AND THERAPY (2021)
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee et al.
LANCET NEUROLOGY (2020)
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
Chao Zhang et al.
LANCET NEUROLOGY (2020)
Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica
Agnieshka M. Agasing et al.
NATURE COMMUNICATIONS (2020)
Neuromyelitis optica
Sven Jarius et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
Kazuo Fujihara et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects
Staley A. Brod
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
S. J. Pittock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce A. C. Cree et al.
LANCET (2019)
Novel emerging treatments for NMOSD
Krzysztof Selmaj et al.
NEUROLOGIA I NEUROCHIRURGIA POLSKA (2019)
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Takashi Yamamura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients
Ciro Romano et al.
CLINICAL RHEUMATOLOGY (2018)
Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
Nadja Borisow et al.
FRONTIERS IN NEUROLOGY (2018)
Neurodegeneration in multiple sclerosis and neuromyelitis optica
Izumi Kawachi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients
Shahd H. M. Hamid et al.
JOURNAL OF NEUROLOGY (2017)
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro
Yukio Takeshita et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
Remi A. Kessler et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2016)
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders
Ingo Kleiter et al.
NEUROTHERAPEUTICS (2016)
Th17 cells in neuromyelitis optica spectrum disorder: a review
Jie Lin et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2016)
Neuromyelitis optica spectrum disorders Comparison according to the phenotype and serostatus
Maria Sepulveda et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
The Treatment of Neuromyelitis Optica
Markus C. Kowarik et al.
JOURNAL OF NEURO-OPHTHALMOLOGY (2014)
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
Marios C. Papadopoulos et al.
NATURE REVIEWS NEUROLOGY (2014)
Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System
Jiwon Oh et al.
NEUROLOGY RESEARCH INTERNATIONAL (2012)
Interleukin-6 Receptor Inhibition With Tocilizumab and Attainment of Disease Remission in Rheumatoid Arthritis The Role of Acute-Phase Reactants
Josef S. Smolen et al.
ARTHRITIS AND RHEUMATISM (2011)
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
Norio Chihara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
IL-6: Regulator of Treg/Th17 balance
Akihiro Kimura et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6
Akiyuki Uzawa et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
The spectrum of neuromyelitis optica
Dean M. Wingerchuk et al.
LANCET NEUROLOGY (2007)
Revised diagnostic criteria for neuromyelitis optica
D. M. Wingerchuk et al.
NEUROLOGY (2006)
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
VA Lennon et al.
LANCET (2004)
Share Paper
